The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
How Large Is The Alpha Mannosidosis Market Projected To Become By 2030 Based On Its 2026 Valuation?
The alpha mannosidosis market has experienced substantial growth in its size over recent years. It is projected to expand from $17.87 billion in 2025 to $21 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 17.5%. The expansion witnessed in the historic period can be attributed to limited diagnostic infrastructure, low disease awareness, reliance on conventional therapies, fragmented treatment guidelines, and restricted R&D funding.
The alpha mannosidosis market size is anticipated to undergo substantial expansion in the upcoming years. It is forecast to achieve a valuation of $39.41 billion by 2030, progressing at a compound annual growth rate (CAGR) of 17.0%. This projected growth over the forecast period is influenced by factors such as enhanced investment in gene therapies, the rising uptake of enzyme replacement therapies, the development of healthcare infrastructure, innovations in diagnostic technologies, and regulatory support for rare diseases. Prominent trends for the forecast duration encompass early genetic screening initiatives, the creation of orphan drugs, tailored enzyme replacement therapy, the proliferation of rare disease clinics, and cooperative research endeavors.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=4093&type=smp
What Major Growth Drivers Are Shaping The Outlook Of The Alpha Mannosidosis Market?
The increasing demand for precision medicine is anticipated to propel the expansion of the alpha mannosidosis market. This tailored approach to healthcare accounts for individual variations in patients’ genes, environments, and lifestyles to optimize treatment and prevention strategies. Progress in genomic technologies and data analytics, which facilitate more precise identification of genetic variations and their impact on health, is driving the growth of precision medicine. Additionally, the heightened need for personalized treatment options, alongside a growing understanding of the limitations of conventional, one-size-fits-all methods, has stimulated interest in customized healthcare solutions. Precision medicine aids in the creation of targeted therapies specifically designed for the genetic mutations and patient profiles associated with this rare disorder. For instance, in February 2024, data from the Personalized Medicine Coalition (PMC), a US-based nonprofit organization, reported that in 2023 FDA approved 16 new personalized treatments for rare diseases, marking a substantial increase from just six approvals in 2022. Consequently, the rising demand for precision medicine is fostering the growth of the alpha mannosidosis market.
What Segment Groups Are Identified Within The Alpha Mannosidosis Market?
The alpha mannosidosis market covered in this report is segmented –
1) By Therapy Type: Bone Marrow Transplant (BMT), Enzyme Replacement Therapy (ERT), Other Therapies
2) By Indication: Type I, Type II, Type III
3) By End-User: Hospitals, Speciality Clinics
Subsegments:
1) By Bone Marrow Transplant (BMT): Autologous BMT, Allogeneic BMT
2) By Enzyme Replacement Therapy (ERT): Recombinant Enzymes, Long-acting Enzyme Formulations
3) By Other Therapies: Symptomatic Treatments, Gene Therapy, Supportive Care
What Trends Are Advancing Progress In The Alpha Mannosidosis Market?
Leading companies in the alpha mannosidosis market are concentrating on developing enzyme replacement therapy for this rare condition. This therapy works by introducing exogenous alpha-mannosidase, which helps to mitigate the buildup of mannose-rich oligosaccharides in various tissues and organs. Such accumulation is a defining characteristic of alpha-mannosidosis and contributes to its pathological effects. For example, in February 2023, Chiesi Global Rare Diseases, a US-based pharmaceutical company, introduced Lamzede (velmanase alfa), marking it as the first enzyme replacement therapy authorized in the United States for treating alpha-mannosidosis, a rare genetic condition characterized by the absence of the alpha-mannosidase enzyme in the body, and its non-central nervous system manifestations. Lamzede restores normal cellular activity in patients by mimicking the function of the human body’s alpha-mannosidase enzyme. Patients receive an injection of 10 mg of Lamzede once per week.
Which Companies Hold Significant Positions In The Alpha Mannosidosis Market?
Major companies operating in the alpha mannosidosis market are Chiesi Farmaceutici S.p.A., Cipla, Daiichi Sankyo Company, Ultragenyx Pharmaceutical Inc, Mitsubishi Tanabe Pharma, Zymenex A/S, Albumedix Ltd, Freeline Therapeutics, Avectas, DiNAQOR AG, Vivet Therapeutics, Herantis Pharma Plc, PTC Therapeutics, Biocad, Sanofi, Orchard Therapeutics, Shire Pharmaceuticals, Amicus Therapeutics, BioMarin Pharmaceutical Inc, Genzyme
Read the full alpha mannosidosis market report here:
https://www.thebusinessresearchcompany.com/report/alphas-mannosidosis-global-market-report
Which Regions Are Projected To Dominate The Alpha Mannosidosis Market In The Coming Years?
North America was the largest region in the alpha mannosidosis market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the alpha mannosidosis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored Alpha Mannosidosis Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=4093&type=smp
Browse Through More Reports Similar to the Global Alpha Mannosidosis Market 2026, By The Business Research Company
Alpha Mannosidosis Market 2026
https://www.thebusinessresearchcompany.com/report/alpha-mannosidosis-global-market
Mannan Oligosaccharide Market Report 2026
https://www.thebusinessresearchcompany.com/report/mannan-oligosaccharide-global-market-report
Immunoassay Market Report 2026
https://www.thebusinessresearchcompany.com/report/immunoassay-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model